NCT03678883 2026-04-039-ING-41 in Patients With Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT05882734 2026-02-17Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)EMD SeronoPhase 1/2 Active not recruiting61 enrolled
NCT05054725 2026-01-06Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesRevolution Medicines, Inc.Phase 2 Completed47 enrolled 17 charts
NCT04774952 2025-04-15Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Completed58 enrolled
NCT05128487 2024-11-25A Study of NDI 1150-101 in Patients With Solid TumorsNimbus TherapeuticsPhase 1/2 Active not recruiting106 enrolled
NCT04800822 2024-10-22PF-07284892 in Participants With Advanced Solid TumorsPfizerPhase 1 Terminated53 enrolled
NCT04768296 2024-09-26Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)EMD SeronoPhase 2 Completed76 enrolled 42 charts
NCT02961283 2023-05-09Study of ASN003 in Subjects With Advanced Solid TumorsAsana BioSciencesPhase 1 Terminated24 enrolled
NCT01204099 2018-05-16Study of PX-866 and Docetaxel in Solid TumorsSeagen Inc.Phase 1/2 Completed223 enrolled
NCT01470209 2018-03-19A Phase I Study of BKM120 and Everolimus in Advanced Solid MalignanciesEmory UniversityPhase 1 Completed43 enrolled